Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: A phase III, randomized, double-blind, fixed-dose, placebo-controlled study

Journal of Psychiatry and Neuroscience

Volumn 39, Issue 1, 2014, Pages 40-49

  Bakish, David ^a   Bose, Anjana ^b   Gommoll, Carl ^b   Chen, Changzheng ^b   Nunez, Rene ^b   Greenberg, William M ^b   Liebowitz, Michael ^c   Khan, Arif ^d,e  

^a Ottawa Psychopharmacology Clinic   (Canada)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Howard Hughes Medical Institute   (United States)

^d Northwest Clinical Research Center   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MILNACIPRAN; PLACEBO; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ERECTILE DYSFUNCTION; EVALUATION AND FOLLOW UP; FEMALE; HEADACHE; HEART DISEASE; HUMAN; HYPERHIDROSIS; INCIDENCE; INTUSSUSCEPTION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; NONCARDIAC CHEST PAIN; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCROTAL PAIN; SENSITIVITY ANALYSIS; SHEEHAN DISABILITY SCALE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT OBSTRUCTION; XEROSTOMIA; ADOLESCENT; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891816383     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.130040     Document Type: Article

References (29)

1. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851-8.
2. Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev 2007;27:959-85.
3. Rush AJ. The varied clinical presentations of major depressive disorder. J Clin Psychiatry 2007;68(Suppl 8):4-10.
4. Auclair AL, Martel JC, Assie MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 2013;70:338-47.
5. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succin ate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65.
6. Asnis GM, Bose A, Gommoll CP, et al. The efficacy and safety of levomilnacipran SR 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase III, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013;74:242-8.
7. Montgomery SA, Mansuy L, Ruth A, et al. The efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2013;74:363-9.
8. Sambunaris A, Bose A, Gommoll C, et al. A Phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran ER in patients with major depressive disorder. J Clin Psychopharmacol. In press.
9. Gommoll C, Bose A, Li H, et al. A randomized double-blind, placebocontrolled, flexible-dose study of levomilnacipran in patients with major depressive disorder [poster]. The 24th Annual US Psychiatric and Mental Health Congress; 2011 Nov. 7-10; Las Vegas, NV.
10. thed. Text rev. Washington (DC): American Psychiatric Association; 2000.
11. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33.
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
13. Guy W. ECDEU Assessment manual for psychopharmacology. In Clinical global impressions. Rockville (MD): National Institute of Mental Health; 1976. p. 218-222.
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
15. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77.
16. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(suppl 3):89-95.
17. Hochberg Y, Tamhane AC. Multiple comparison procedures. New York (NY): John Wiley & Sons; 1987.
18. Kenward MG, Molenberghs G, Thijs H. Pattern-mixture models with proper time dependence. Biometrika 2003;90:53-71.
19. Sheehan DV, Harnett-Sheehan K, Spann ME, et al. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol 2011;26:75-83.
20. Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 2008;23:70-83.
21. Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008;48:1680-9.
22. Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 2009;24:111-8.
23. Israel JA. Remission in depression: definition and initial treatment approaches. J Psychopharmacol 2006;20:5-10.
24. Solomon DA, Leon AC, Coryell W, et al. Predicting recovery from episodes of major depression. J Affect Disord 2008;107:285-91.
25. Thase ME. The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists? Curr Psychiatry Rep 2011; 13: 476-82.
26. Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007;68:1062-70.
27. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-47.
28. Indik JH, Pearson EC, Fried K, et al. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 2006;3:1003-7.
29. Malik M. Problems of heart rate correction in assessment of druginduced QT interval prolongation. J Cardiovasc Electrophysiol 2001; 12:411-20.